According to BL Pharmtech’s interim report released on the 14th, consolidated revenue for the first half of this year was 1.373 billion won, a 71.3% decrease from 4.788 billion won in the same period last year. The operating loss widened to 1.291 billion won from 1.179 billion won in the same period last year. The net loss for the first half was 1.14 billion won, down from 1.917 billion won in the same period last year.
This interim report reflects revisions to the standalone results for the first quarter. In its first-quarter report, BL Pharmtech had reported standalone revenue of 1.214 billion won and operating profit of 290 million won. However, during the interim review process, strict accounting standards were applied, resulting in revenue being revised downward to 357 million won and operating profit being revised to a loss of 567 million won.
However, the company dismissed shareholders’ concerns that the decline in revenue could affect its ability to maintain its listing status.
A representative from BL Pharmtech stated, “From the beginning of this year through the present, our average daily market capitalization has reached 75 billion won, which already significantly exceeds the 60 billion won threshold required for an exemption from delisting due to insufficient revenue,” adding, “We do not meet any of the delisting criteria, whether related to insufficient revenue, penny stock status, or insufficient market capitalization.”
The official added, “We are devoting all our efforts to expanding our online commerce presence and strengthening global sales as soon as possible to boost revenue and enhance shareholder value.”
In fact, BL Pharmtech has signed a strategic memorandum of understanding (MOU) with Dinos Studio, a global social commerce specialist, and is embarking on a full-scale diversification of its distribution channels. The company plans to move beyond its existing TV home shopping-centric distribution structure and target global markets—including the U.S., Japan, Vietnam, Malaysia, and Singapore—through Dinos Studio’s YouTube and TikTok channels.
Key product lines for this collaboration include the women’s health diagnostic kit “Gynpad,” “Dr. Fits”—which utilizes a GLP-1 activation mechanism—and “GLP-1-Promoting Probiotics for Weight Management,” scheduled for release in the second half of the year.
A representative from BL Pharmtech stated, “We are also actively pursuing the acquisition of businesses that are generating stable sales and operating profits,” adding, “By simultaneously generating new commerce revenue through our strategic partnership with Dinos Studio and acquiring stable, profitable businesses, we will achieve not only future growth through the success of innovative new drug development but also solid financial stability.”
